spacer
home > ebr > spring 2018 > redefining proteomics
PUBLICATIONS
European Biopharmaceutical Review

Redefining Proteomics

Tumour suppressor p53 (TP53) is a gene, not a protein. It is rhetorically convenient but scientifically inaccurate to suggest these are morphological variants of the same thing. Human cells splice and assemble in at least nine different ways the exons present in the TP53 gene. Therefore, TP53 isoform 7 is the appropriate name for an mRNA intermediary between gene and protein. Likewise, protein does not simply swap ribonucleotides for amino acids at a 3:1 ratio.

Many residues will be variously and reversibly modified with chemical, carbohydrate, lipidatious, and/or proteinacious adducts that will impart different structures and biochemical properties; direct the protein to different locations; alter activities, functions, and interactions; and control destruction of the molecule itself – all as the larger cell sees fit. These co- and post-translational modifications (PTM) are essential to everything about proteins that makes them so. Methylated, phospho-TP53 isoform 7 is thus a protein. If a proteomic screen is not providing this level of information, is it technically even proteomic?

Mass Spectrometry: Necessary but Insufficient

Stable proteins may have no concurrently existing, corresponding mRNA. Post-transcriptional regulation means not all mRNA present within cells has such corresponding protein. To identify the protein components of a complex sample, no substitute for mass spectrometry (MS) exists, particularly in targeted approaches where one seeks to identify the presence of a particular component within complex mixtures

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Christian Loch is Chief Executive and Science Officer at AVMBioMed. He is also adjunct faculty in the Department of Chemistry at Villanova University, US, where he teaches proteomics in the graduate school. Christian has 10 years of industry experience and holds an MPH in epidemiology from the University of Washington, US, and a PhD in biochemistry from the University of Virginia, US.
spacer
Dr Christian Loch
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Mauritius Island – An Emerging Centre for R&D in Biotechnology and the Life Sciences

CIDP (Centre International de Développement Pharmaceutique)

Mauritius, the tropical island situated in the Indian Ocean and known worldwide for its beautiful beaches, is also internationally recognised for its rule of law, and political and social stability. Over the past few years, the economy has been successfully transitioned from a monocrop to a diversified innovation-driven and knowledge-based economy, resting on agribusiness, export-oriented manufacturing, tourism, financial services, property development and real estate, ICT-BPO, the seafood industry, a free port, logistics and a nascent ocean economy. Emerging sectors such as healthcare and life sciences are presenting some niche areas for the taking, and the enabling environment is being put in place to make it happen - especially in the light of sustained growth within pharmaceutical, medical device, and clinical research. Important international players are already in operation locally as the country has established the appropriate legal and regulatory frameworks based on international norms, for the development of a strong biomedical research sector.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement